NCT07053917View on ClinicalTrials.gov

Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

January 31, 2027

Conditions
StrokeChronic StrokeIntracerebral HaemorrhageIntracerebral Haemorrhage (ICH)Intracerebral Hemorrhage Basal GangliaIschemic StrokeIschemic Stroke and Hemorrhagic StrokeHemiparesis After StrokeHemiplegia Following Ischemic StrokeHemiplegia and HemiparesisHemiplegia and/or Hemiparesis Following StrokeMiddle Cerebral Artery Stroke
Interventions
DRUG

Psilocybin (Usona Institute)

Participants will receive psilocybin to test its safety. Secondary outcomes will assess recovery from post-stroke deficits.

All Listed Sponsors
collaborator

Rose Hill

UNKNOWN

collaborator

Usona Institute

OTHER

lead

Johns Hopkins University

OTHER